Fig. 4: FYN-TRAF3IP2 activates TRAF6 and canonical NF-κB signaling independent of the CBM signalosome.

a Western blot analysis of whole-cell lysate and anti-TRAF6 immunoprecipitate in TRAF3IP2-, FYN-TRAF3IP2- and FYN-TRAF3IP2ΔT6-expressing Jurkat cells. b Western blot analysis of whole-cell lysate and anti-TRAF3IP2 immunoprecipitate in TRAF3IP2-, FYN-TRAF3IP2- and FYN-TRAF3IP2ΔT6-expressing Jurkat cells. c Outgrowth of Ba/F3 cells transduced with pMIG-FYN-TRAF3IP2 or pMIG-FYN-TRAF3IP2ΔT6 after withdrawal of IL-3. n = 3 biological replicates per condition. d Western blot analysis for canonical NF-κB activation in Jurkat cells transduced with pMIG-TRAF3IP2, pMIG-FYN-TRAF3IP2 or pMIG-FYN-TRAF3IP2ΔT6. e Intracellular flow cytometry for phospho-p65 in resting CD4+ T cells with expression of TRAF3IP2, FYN-TRAF3IP2 or FYN-TRAF3IP2ΔT6 . n = 3 biological replicates per condition. p values were calculated with Tukey’s post-hoc multiple comparisons test. f NF-κB luciferase reporter signal intensity in wild-type Jurkat cells (left) or CARD11 knock-out Jurkat cells (right) with empty control vector or expression of TRAF3IP2, FYN-TRAF3IP2 or FYN-TRAF3IP2ΔT6 in resting conditions or after stimulation with PMA. n = 4 biological replicates per condition. p values were calculated with Tukey’s post-hoc multiple comparisons test. All data are represented as mean ± SD.